DOCSLIB.ORG

2021 Emerald Coast Veterinary Conference

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

COVER 4 COVER 1 Mark your Calendars for the next ECVC! 2021 Emerald Coast Veterinary Conference 2022 EMERALD COAST VETERINARY CONFERENCE June 1-5, 2022 Sandestin Golf & Beach Resort Destin, Florida 2021 Proceedings ECVC is presented by the Alabama and Georgia Veterinary Medical Associations ECVC is presented by the Alabama and Georgia Veterinary Medical Associations 73183 ECVC_covers_mp.indd 1 5/27/2021 7:36:09 AM Table of Contents Proceedings of the 2021 Emerald Coast Veterinary Conference Listed by day, in Program Schedule. Thursday, July 8, 2021 Keynote Address Jedi Mind Trick .........................................................................................................................1 Andy Roark, DVM Pathology Pairing CBC Data with Bone Marrow Evaluation, a Case-Based Approach ........................4 Erica Behling-Kelly, DVM, PhD, DACVP Evaluation of Body Cavity Fluids ............................................................................................5 Erica Behling-Kelly, DVM, PhD, DACVP Cytological Review of Common Skin Lesions and Lymph Node Aspirates ............................6 Erica Behling-Kelly, DVM, PhD, DACVP Ophthalmology The Corneal Colors ...................................................................................................................7 Kathryn Diehl, DVM, MS, DACVO The Lens and Cataracts ..........................................................................................................19 Kathryn Diehl, DVM, MS, DACVO Get to Know the Nictitating Membrane .................................................................................29 Kathryn Diehl, DVM, MS, DACVO Parasitology Canine Heartworm Disease ....................................................................................................43 Chris Adolph, DVM, MS, DACVM (Parasitology) Canine Ectoparasites ..............................................................................................................45 Chris Adolph, DVM, MS, DACVM (Parasitology) Gastroenterology Doggie Diarrhea: The Microbiome, Pre-and Probiotics and What This Means for K9 Gut Health in 2021 ..................................................................................................................48 Michelle Evason, DVM, BSc, DACVIM Canine Parvovirus: Updates on Evidence-Based Spectrum of Care Therapy Considerations .........................................................................................................................51 Michelle Evason, DVM, BSc, DACVIM Clinical Nutrition: Alternative Diets (Raw and Homemade): Risks, Rewards and Pet- Owner Decision Making .........................................................................................................58 Michelle Evason, DVM, BSc, DACVIM Feline Medicine Case-Based Approach to Chronic Vomiting in Cats .............................................................63 Deb Zoran, DVM, PhD, DACVIM Kitten Diarrhea .......................................................................................................................66 Deb Zoran, DVM, PhD, DACVIM The Feline Pancreas: From Acute to Chronic Pancreatitis and Insufficiency ...................70 Deb Zoran, DVM, PhD, DACVIM Constipation in Cats: Prevention and Management Strategies ............................................73 Deb Zoran, DVM, PhD, DACVIM USDA Module 5: Vesicular Disease ..................................................................................................78 Mel Stephens, DVM Module 9: Interstate and International Health Certificates for Category I Animals ..........79 Mel Stephens, DVM Module 21: Animals’ Fitness to Travel ..................................................................................80 Mel Stephens, DVM Module 29: Veterinary Feed Directives .................................................................................81 Mel Stephens, DVM Friday, July 9, 2021 Geriatrics Cognition and Optimal Brain Function in Older Dogs ........................................................85 Maureen McMichael, DVM, M. Ed. DACVECC Microbiome Update: How it Changes with Age, and How to Optimize it For Your Older Pet Population ...............................................................................................................93 Maureen McMichael, DVM, M. Ed. DACVECC Hypercoagulable Changes in Older Pets: Mitigation Strategies ........................................102 Maureen McMichael, DVM, M. Ed. DACVECC Oxidative Stress Theory and Select Antioxidants in Aging Pets .........................................109 Maureen McMichael, DVM, M. Ed. DACVECC An Update on Anti-Aging Research Applications for the Geriatric Pet .............................115 Maureen McMichael, DVM, M. Ed. DACVECC Dermatology Where Do I Start with This Pruritic Patient? ......................................................................123 Millie Rosales, DVM, DACVD The New and The Not So New Drugs/ Therapies for Atopy ...............................................127 Millie Rosales, DVM, DACVD Otitis in Dogs .........................................................................................................................133 Millie Rosales, DVM, DACVD Paws and Claws: Conditions That Affect the Feet of Dogs ................................................140 Millie Rosales, DVM, DACVD Dermatology Pearls ...............................................................................................................148 Millie Rosales, DVM, DACVD Practice Management Part 1: Using Technology to Deliver a Better Experience for Your Clients and Your Team ......................................................................................................................................151 Stacee Santi, DVM Part 2: Technology Tools to Communicate with Your Veterinary Team ...........................153 Stacee Santi, DVM How to Build a Loyalty Program That Boosts Revenue and Retention..............................156 Stacee Santi, DVM Pet Owners Have Spoken: You’re Doing It Wrong! Client Communication Preferences for Medical Updates .........................................................................................160 Stacee Santi, DVM The 5 Step Pharmacy Program: Success Tips to Maximizing Your Pharmacy Revenue in a Chewy World ..................................................................................................................162 Stacee Santi, DVM Cardiology The ABCs of ECGs Part I .....................................................................................................164 Meg Sleeper, VMD, DACVIM (Cardiology) The ABCs of ECGs Part II ...................................................................................................167 Meg Sleeper, VMD, DACVIM (Cardiology) Current Recommendations for Treating Dogs with Degenerative Valve Disease .............171 Meg Sleeper, VMD, DACVIM (Cardiology) Dilated Cardiomyopathy and Current Recommendations for Therapy ..............................174 Meg Sleeper, VMD, DACVIM (Cardiology) Update on Managing Feline Heart Disease.........................................................................176 Meg Sleeper, VMD, DACVIM (Cardiology) Exotics Rabbit Diseases: Practical, Diagnostic, and Treatment Options ........................................180 Cheryl Greenacre, DVM, DABVP (Avian Practice), DABVP (Exotic Companion Mammal) Rabbit and Guinea Pig Surgery ...........................................................................................187 Cheryl Greenacre, DVM, DABVP (Avian Practice), DABVP (Exotic Companion Mammal) Medication Use in Backyard Poultry ...................................................................................194 Cheryl Greenacre, DVM, DABVP (Avian Practice), DABVP (Exotic Companion Mammal) Musculoskeletal Cruciate Injury and Repair in the Dog ................................................................................197 Steve Budsberg, DVM Obesity and Musculoskeletal Problems ................................................................................202 Steve Budsberg, DVM Antimicrobial Prophylaxis in Orthopedic Surgery ..............................................................205 Steve Budsberg, DVM Treatment of Osteoarthritis in Dogs and Cats .....................................................................207 Steve Budsberg, DVM NSAIDS in the Management of Chronic Pain ....................................................................215 Steve Budsberg, DVM Saturday, July 10, 2021 Anesthesiology Anesthesia Crises ..................................................................................................................225 Erik Hofmeister, DVM, DACVAA, DECVAA MA MS Communicating Anesthesia Risk to Client ..........................................................................241 Erik Hofmeister, DVM, DACVAA, DECVAA MA MS Medical Error ........................................................................................................................250 Erik Hofmeister, DVM, DACVAA, DECVAA MA MS Newer Anesthesia Drugs .......................................................................................................263 Erik Hofmeister, DVM, DACVAA, DECVAA MA MS Pain Management Alternatives ............................................................................................282 Erik Hofmeister, DVM, DACVAA, DECVAA MA MS Pharmacology Pharmacy Law .......................................................................................................................297 Susan Elrod, BS, PharmD, PhD Veterinary
Recommended publications
  • US EPA, Pesticide Product Label, LESCO PRE-M 1.5% PLUS FERTILIZER ,04/13/2021

    US EPA, Pesticide Product Label, LESCO PRE-M 1.5% PLUS FERTILIZER ,04/13/2021

    UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, DC 20460 OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION April 13, 2021 Viviana Torres LESCO Inc. Assistant Regulatory Manager 1385 East 36th St. Cleveland, OH 44114-4114 Subject: Registration Review Label Mitigation for Pendimethalin Product Name: LESCO PRE-M 1.5% PLUS FERTILIZER EPA Registration Number: 10404-98 Application Date: 06/28/2018 Decision Number: 567191 Dear Ms. Torres: The Agency, in accordance with the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), as amended, has completed reviewing all the information submitted with your application to support the Registration Review of the above referenced product in connection with the Pendimethalin Interim Decision, and has concluded that your submission is acceptable. The label referred to above, submitted in connection with registration under FIFRA, as amended, is acceptable. Should you wish to add/retain a reference to the company’s website on your label, then please be aware that the website becomes labeling under the Federal Insecticide Fungicide and Rodenticide Act and is subject to review by the Agency. If the website is false or misleading, the product would be misbranded and unlawful to sell or distribute under FIFRA section 12(a)(1)(E). 40 CFR 156.10(a)(5) list examples of statements EPA may consider false or misleading. In addition, regardless of whether a website is referenced on your product’s label, claims made on the website may not substantially differ from those claims approved through the registration process. Therefore, should the Agency find or if it is brought to our attention that a website contains false or misleading statements or claims substantially differing from the EPA approved registration, the website will be referred to the EPA’s Office of Enforcement and Compliance.
  • FF #93 THC Cancer AIDS.3Rd Ed

    FF #93 THC Cancer AIDS.3Rd Ed

    ! FAST FACTS AND CONCEPTS #93 CANNABINOIDS IN THE TREATMENT OF SYMPTOMS IN CANCER AND AIDS L Scott Wilner MD and Robert M Arnold MD Introduction The healing properties of cannabis have been asserted for centuries. Popular claims notwithstanding, there are no data to support the use of marijuana in the treatment of asthma, anxiety, depression, epilepsy, glaucoma, alcohol withdrawal, or infection; and limited data to support using cannabinoids as analgesics. Recent scientific studies of cannabinoids for symptom management have focused on nausea/vomiting and appetite stimulation. Terminology Cannabis sativa is the Indian hemp plant. Marijuana is a psychoactive substance derived from the plant. Cannabinoids are the biologically active compounds in the plant. THC is delta )-9 tetrahydrocannabinol, the major cannabinoid. Dronabinol is synthetic THC and the main ingredient in the Schedule 3 drug Marinol. Nabilone is an engineered THC analog that forms the basis of the Schedule 2 drug Cesamet. Pharmacology Cannabinoids act on cannabinoid receptors: the CB1 receptor in the CNS and on the CB2 receptor localized primarily to immune cells. Dronabinol and nabilone are well absorbed orally, but first pass metabolism and protein binding limit bioavailability. Dronabinol has a faster onset of action (~30 minutes), while nabilone has a longer duration of action (typically 8 – 12 hours, but potentially as long as 24 hours in some patients). Alternative delivery systems – including inhalers, suppositories, and transdermal patches – are being evaluated. Anti-emetic Use Dronabinol and nabilone are FDA approved for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetics.
  • Pharmacologic Interventions for Fatigue in Cancer and Transplantation: a Meta-Analysis

    Pharmacologic Interventions for Fatigue in Cancer and Transplantation: a Meta-Analysis

    DRUG INTERVENTIONS FOR FATIGUE, Tomlinson et al. REVIEW ARTICLE Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis † † ‡ D. Tomlinson RN MN,* P.D. Robinson MD MSc, S. Oberoi MD, D. Cataudella PsyD CPsych, § || # N. Culos-Reed PhD, H. Davis,* N. Duong,* F. Gibson RN PhD, M. Götte PhD, P. Hinds RN PhD,** †† †† † ‡‡ §§ S.L. Nijhof MD PhD, P. van der Torre, S. Cabral, L.L. Dupuis MScPhm PhD,* and L. Sung MD PhD* ABSTRACT Background Our objective was to determine whether, compared with control interventions, pharmacologic interventions reduce the severity of fatigue in patients with cancer or recipients of hematopoietic stem-cell transplantation (hsct). Methods For a systematic review, we searched medline, embase, the Cochrane Central Register of Controlled Trials, cinahl, and Psychinfo for randomized trials of systemic pharmacologic interventions for the management of fatigue in patients with cancer or recipients of hsct. Two authors independently identified studies and abstracted data. Methodologic quality was assessed using the Cochrane Risk of Bias tool. The primary outcome was fatigue severity measured using various fatigue scales. Data were synthesized using random-effects models. Results In the 117 included trials (19,819 patients), the pharmacologic agents used were erythropoietins (n = 31), stimulants (n = 19), l-carnitine (n = 6), corticosteroids (n = 5), antidepressants (n = 5), appetite stimulants (n = 3), and other agents (n = 48). Fatigue was significantly reduced with erythropoietin [standardized mean difference (smd): –0.52; 95% confidence interval (ci): –0.89 to –0.14] and with methylphenidate (smd: –0.36; 95% ci: –0.56 to –0.15); modafinil (or armodafinil) and corticosteroids were not effective.
  • 9Th SAVE Report

    9Th SAVE Report

    Report of 9th Annual Meeting of Saving Asia’s Vultures from Extinction 4-6th November 2019 Pinjore, India Contents 1. About SAVE and this report 1-3 2. Updated SAVE priorities for vulture conservation in 2019 2.1 Priorities South Asia 4 2.2 Priorities South East Asia 5 3. Overview of selected SAVE activities since 8th SAVE meeting 3.1 Outstanding achievements/updates of 2019 6-8 3.2 Emerging concerns 8 3.3 The SAVE Blueprint 9 3.4 Changes regarding SAVE Partners 9 3.5 New SAVE Partners 9 3.6 Website 10 4. Progress Summary (traffic lights) for all Blueprint activities 4.1 Status in 2019 11 4.2 Status in 2018 (for comparison) 12 5. 2019 Composition of the SAVE partnership 13- 14 6. Main report: SAVE Partners 2019 updates by Country 6.1 General SAVE actions 14 6.2 India 19 6.3 Nepal 32 6.4 Bangladesh 40 6.5 Pakistan 45 6.6 Cambodia 52 6.7 Myanmar 58 7. SAVE Associates Reports 63 8. Additional Reports received relevant to SAVE Priorities from South 69 Africa 9. Additional Reports received relevant to SAVE Priorities from India 69 10. Reports received relevant to SAVE Priorities from the Middle East 74 11. Fundraising Reports 78 Annex 1. Programme of 9th Annual SAVE Meeting – Parwanoo, India 83 Annex 2. List of Meeting Attendees 86 Annex 3. Updated SAVE Blueprint for 2020 88 Annex 4. List of Acronyms and Abbreviations 108 1. About SAVE and this report The SAVE consortium, originally of eleven (now 24) organisations was formally established in February 2011 under the banner ‘Saving Asia’s Vultures from Extinction’ (SAVE).
  • Megestrol Acetate: Drug Information

    Megestrol Acetate: Drug Information

    Official reprint from UpToDate® www.uptodate.com ©2017 UpToDate® Megestrol acetate: Drug information Copyright 1978-2017 Lexicomp, Inc. All rights reserved. (For additional information see "Megestrol acetate: Patient drug information" and see "Megestrol acetate: Pediatric drug information") For abbreviations and symbols that may be used in Lexicomp (show table) Brand Names: US Megace ES; Megace Oral Brand Names: Canada Megace OS; Megestrol Pharmacologic Category Antineoplastic Agent, Hormone; Appetite Stimulant; Progestin Dosing: Adult Note: Megace ES suspension is not equivalent to other formulations on a mg-per-mg basis. Anorexia or cachexia associated with AIDS: Oral: Suspension: U.S. labeling: Initial: 625 mg daily (of the 125 mg/mL suspension) or 800 mg daily (of the 40 mg/mL suspension); daily doses of 400 mg to 800 mg have been found to be effective Canadian labeling: Usual dose: 400 to 800 mg once daily for at least 2 months Breast cancer, advanced: Oral: Tablet: U.S. labeling: 160 mg per day in divided doses of 40 mg 4 times daily for at least 2 months Canadian labeling: 160 mg or 125 mg/m2 daily (40 mg 4 times daily or 160 mg once daily) for at least 2 months Endometrial cancer, advanced: Oral: Tablet: U.S. labeling: 40 to 320 mg daily in divided doses for at least 2 months Canadian labeling: 80 to 320 mg or 62.5 to 250 mg/m2 daily in divided doses (40 to 80 mg 1 to 4 times daily or 160 to 320mg daily) for at least 2 months Cancer-related cachexia: Canadian labeling: Oral: Tablet: 400 to 800 mg once daily for at least 2 months Cancer-related cachexia (off-label use/dosing in U.S.): Oral: Doses ranging from 160 to 800 mg per day were effective in achieving weight gain, higher doses (>160 mg) were associated with more weight gain (Beller, 1997; Loprinzi, 1990; Loprinzi, 1993; Vadell, 1998); based on a meta-analysis, an optimal dose has not been determined (Ruiz Garcia, 2013) Dosing: Geriatric Use with caution; refer to adult dosing.
  • From the Canadian Food Inspection Agency Annex E

    From the Canadian Food Inspection Agency Annex E

    From the Canadian Food Inspection Agency http://www.inspection.gc.ca/english/fssa/meavia/man/ch17/annexee.shtml#e6 Annex E Table of Contents E.1 Introduction E.2 Equine Information Document E.3 Equine Written Description Terms E.4 Equine Lot Program E.5 List of Veterinary Dugs Not Permitted For Use in Equine Slaughtered For Food With Canadian Brand Name Examples E.6 List of "Essential" Veterinary Drugs Permitted in Equine With a 6 Month Withdrawal Period With Canadian Brand Name Examples E.7 List of Veterinary Drugs Safe for Use in Equine Intended for Food Production for Which Withdrawal Periods Have Been Determined with Canadian Brand Name Examples E.8 Frequently Asked Questions and Answers E.1 Introduction Effective July 31, 2010, it will be mandatory for all Canadian Food Inspection Agency (CFIA) inspected facilities in Canada engaged in equine slaughter for edible purposes to have complete records for all animals (domestic and imported) presented for slaughter. These records will include unique identification for each animal, a record of illness and a record of medical treatments administered to the animal for the six-month period preceding slaughter. The template entitled "Equine Information Document" (EID) of this annex (see E.2) shall be used by equine owners to provide the required information for individual equine animals. A completed individual animal EID contains a standardized description of the animal, as well as a comprehensive record of the equine's medical treatment for at least the preceding six months. The various options for identification, including visual and written descriptions, are listed in the EID.
  • WSAVA List of Essential Medicines for Cats and Dogs

    WSAVA List of Essential Medicines for Cats and Dogs

    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
  • Étude De La Résistance Aux Antibiotiques Des Entérocoques D’Origine Animale Du Québec

    Étude De La Résistance Aux Antibiotiques Des Entérocoques D’Origine Animale Du Québec

    Université de Montréal Étude de la résistance aux antibiotiques des entérocoques d’origine animale du Québec par Cindy-Love Tremblay GREMIP et CRIP Département de pathologie et microbiologie Faculté de médecine vétérinaire Thèse présentée à la Faculté de médecine vétérinaire en vue de l’obtention du grade de philosophiae doctor (Ph.D.) en sciences vétérinaires option microbiologie Août 2012 Cindy-Love Tremblay, 2012 ii RÉSUMÉ Les entérocoques font partie de la flore normale intestinale des animaux et des humains. Plusieurs études ont démontré que les entérocoques d’origine animale pouvaient représenter un réservoir de gènes de résistance aux antibiotiques pour la communauté humaine et animale. Les espèces Enterococcus faecalis et Enterococcus faecium sont importantes en santé publique; elles sont responsables d’environ 12% de toutes les infections nosocomiales aux États-Unis. Au Canada, les cas de colonisation et/ou d’infections à entérocoques résistants à la vancomycine ont plus que triplé de 2005 à 2009. Un total de 387 isolats E. faecalis et E. faecium aviaires, et 124 isolats E. faecalis porcins ont été identifiés et analysés pour leur susceptibilité aux antibiotiques. De hauts pourcentages de résistance envers les macrolides et les tétracyclines ont été observés tant chez les isolats aviaires que porcins. Deux profils phénotypiques prédominants ont été déterminés et analysés par PCR et séquençage pour la présence de gènes de résistance aux antibiotiques. Différentes combinaisons de gènes de résistance ont été identifiées dont erm(B) et tet(M) étant les plus prévalents. Des extractions plasmidiques et des analyses par hybridation ont permis de déterminer, pour la première fois, la colocalisation des gènes erm(B) et tet(M) sur un plasmide d’environ 9 kb chez des isolats E.
  • Grayanotoxin Poisoning in Humans from Honey Consumption HELENA COLOMA DÍEZ AUTONOMOUS UNIVERSITY of BARCELONA

    Grayanotoxin Poisoning in Humans from Honey Consumption HELENA COLOMA DÍEZ AUTONOMOUS UNIVERSITY of BARCELONA

    Grayanotoxin Poisoning in Humans from Honey Consumption HELENA COLOMA DÍEZ AUTONOMOUS UNIVERSITY OF BARCELONA Objectives Structure, Types and Isolation of GTX The main objective of this bibliographic research is compiling and announcing information Grayanotoxins are non-volatile diterpenes, a about grayanotoxin-containing honey and the toxic effects derived from its ingestion. This polyhidroxylated cyclic hydrocarbon with a 5/7/6/5 ring substance is believed to have medicinal properties, and the current increment of use of structure that does not contain nitrogen, as seen on figure 2. There are 25 known isoforms of grayanotoxins, natural products as dietetic complements with this finality may cause a rising in the number GTX-I and GTX-III being the most common and of intoxication cases. So it is important learning to recognise the clinical signs it causes and abundant ones, followed by GTX-II. their treatment, apart from finding out if it may have medicinal applications. TheGTXcanbeisolatedbytypicalextraction procedures for naturally occurring terpenes, such as paper electrophoresis, thin-layer chromatography (TLC), and gas chromatography (GC). They require derivatization before GC analysis due to the Introduction compound’s instability on heating and having low vapor pressure. Other identification techniques are based on The poisoning caused by grayanotoxin-containing honey, called “mad honey”, is known from infrared (IR), nuclear magnetic resonance (NMR), and antiquity. This toxic honey has been used for different purposes, such as biological weapon mass spectrometry (MS). or therapeutical product. Figure 2. Structure formulas (left pannel) and 3D The origin of this toxin relays in some plants of the Rhododendron genus, widespread all representations (right pannel) of GTX-I, II and III.
  • Generic Name Brand Name

    Generic Name Brand Name

    Florida AIDS Drug Assistance Program (ADAP) Formulary MAY 2021 *Indicates controlled substance. Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability. Brand Name (listed for Generic Name Therapeutic Classification Pharmacologic Classification Antiretroviral drugs only) abacavir (ABC) Ziagen Antiretroviral Nucleoside reverse transcriptase inhibitor (NRTI) abacavir/lamivudine (ABC/3TC) Epzicom Antiretroviral NRTI combo abacavir/lamivudine/zidovudine (ABC/3TC/AZT) Trizivir Antiretroviral NRTI combo atazanavir (ATV) Reyataz Antiretroviral Protease inhibitor (PI) atazanavir/cobicistat (ATV/COBI) Evotaz Antiretroviral PI/PK Enhancer bictegravir/emtricitabine/tenofovir alafenamide Biktarvy Antiretroviral INSTI/NRTI combo (BIC/TAF/FTC) cabotegravir Vocabria Antiretroviral INSTI Non-nucleoside reverse transcriptase inhibitor (NNRTI) cabotegravir/rilpivirine (CBV/RPV) Cabenuva Antiretroviral and INSTI cobicistat (COBI) Tybost Antiretroviral Pharmacokinetic enhancer darunavir (DRV) Prezista Antiretroviral Protease inhibitor (PI) darunavir/cobicistat (DRV/COBI) Prezcobix Antiretroviral PI/PK Enhancer darunavir/cobicistat/emtricitabine/tenofovir Symtuza Antiretroviral PI/NRTI combo alafenamide (DRV/COBI/FTC/TAF) dolutegravir (DTG) Tivicay Antiretroviral Integrase strand transfer inhibitor (INSTI) dolutegravir / lamivudine (DTG/3TC) Dovato Antiretroviral INSTI/NRTI combo dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) Triumeq Antiretroviral INSTI/NRTI combo dolutegravir/rilpivirine (DTG/RPV) Juluca
  • Arrian's Voyage Round the Euxine

    Arrian's Voyage Round the Euxine

    — T.('vn.l,r fuipf ARRIAN'S VOYAGE ROUND THE EUXINE SEA TRANSLATED $ AND ACCOMPANIED WITH A GEOGRAPHICAL DISSERTATION, AND MAPS. TO WHICH ARE ADDED THREE DISCOURSES, Euxine Sea. I. On the Trade to the Eqft Indies by means of the failed II. On the Di/lance which the Ships ofAntiquity ufually in twenty-four Hours. TIL On the Meafure of the Olympic Stadium. OXFORD: DAVIES SOLD BY J. COOKE; AND BY MESSRS. CADELL AND r STRAND, LONDON. 1805. S.. Collingwood, Printer, Oxford, TO THE EMPEROR CAESAR ADRIAN AUGUSTUS, ARRIAN WISHETH HEALTH AND PROSPERITY. We came in the courfe of our voyage to Trapezus, a Greek city in a maritime fituation, a colony from Sinope, as we are in- formed by Xenophon, the celebrated Hiftorian. We furveyed the Euxine fea with the greater pleafure, as we viewed it from the lame fpot, whence both Xenophon and Yourfelf had formerly ob- ferved it. Two altars of rough Hone are ftill landing there ; but, from the coarfenefs of the materials, the letters infcribed upon them are indiftincliy engraven, and the Infcription itfelf is incor- rectly written, as is common among barbarous people. I deter- mined therefore to erect altars of marble, and to engrave the In- fcription in well marked and diftinct characters. Your Statue, which Hands there, has merit in the idea of the figure, and of the defign, as it reprefents You pointing towards the fea; but it bears no refemblance to the Original, and the execution is in other re- fpects but indifferent. Send therefore a Statue worthy to be called Yours, and of a fimilar delign to the one which is there at prefent, b as 2 ARYAN'S PERIPLUS as the fituation is well calculated for perpetuating, by thefe means, the memory of any illuftrious perfon.
  • Cyproheptadine for Central Hypertension?

    Cyproheptadine for Central Hypertension?

    OPEN ACCESS Research article Cyproheptadine for central hypertension? Guido Filler1,2,*, Lara Hart1, April Chan3, Elizabeth Cairney4, Asuri N Prasad5 1Department of Paediatrics, Division of Paediatric Nephrology, Schulich School ABSTRACT of Medicine & Dentistry, London, ON, Background: Approximately one-fifth of paediatric intracranial tumors result in hypertension. Canada N6A 5W9 2Department of Pathology and The condition is difficult to treat in this population, particularly if it is refractory, since there is little Laboratory Medicine, Schulich School of guidance on patient management beyond first-line therapy with IV labetalol. Medicine & Dentistry, University of Western Ontario, London, Ontario, Methods: A 20-month-old patient was hospitalized with cerebral herniation-induced loss of Canada N5A 5A5 consciousness and a posterior fossa mass was found. Although several first-line treatments including 3 School of Pharmacy, University of IV labetalol, furosemide, amlodipine, clonidine, and atenolol were administered, the patient’s Western Ontario, London, ON, Canada 5A 5A5 hypertension persisted. With few options left, positive findings from previously published case reports 4Department of Paediatrics, Division of led the team to administer cyproheptadine. Hematology/Oncology, Schulich School of Medicine & Dentistry, London, ON, Results: Cyproheptadine resulted in improved blood pressure and allowed for a dose reduction in Canada N6A 5W9 other antihypertensives, but elevated liver transaminases and suspected hepatotoxicity several weeks 5 Department of Paediatrics, Division of later resulted in the discontinuation of this treatment. Neurology, Schulich School of Medicine & Dentistry, London, ON, Canada N6A Conclusions: Despite the safety concerns associated with using cyproheptadine to treat paediatric 5W9 central hypertension, this treatment holds promise for persistent refractory hypertension as a last-line *Email: [email protected] agent when all other treatment options are exhausted.